Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma

J Oral Maxillofac Surg. 2011 Sep;69(9):2465-72. doi: 10.1016/j.joms.2011.02.078. Epub 2011 Jul 16.

Abstract

Purpose: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-recognized pathologic entity that is challenging and difficult to manage. Recent literature contains several articles, with most recommending conservative management. This report describes a treatment modality for advanced cases of BRONJ that involves bone resection and autologous platelet-rich plasma (PRP).

Patients and methods: This case series consisted of 25 patients with BRONJ lesions and a history of intravenous bisphosphonate therapy for metastatic bone diseases that did not respond to conservative treatment. All patients were surgically managed by a standardized protocol combining bone resection and PRP.

Results: Of the 25 patients, 20 (80%) showed complete wound healing during follow-up. Median follow-up was 36 months. Microscopic examination showed actinomyces in 15 specimens.

Conclusion: BRONJ has been shown to be refractory to conservative management. Treatment of refractory BRONJ with a combination of bone resection and PRP was found to be an effective therapy in most patients and should be considered an alternative treatment modality for management of advanced cases.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects*
  • Female
  • Humans
  • Injections, Intravenous
  • Jaw Diseases / chemically induced
  • Jaw Diseases / surgery*
  • Male
  • Middle Aged
  • Osteonecrosis / chemically induced
  • Osteonecrosis / surgery*
  • Platelet-Rich Plasma*
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Diphosphonates